Trizell Group

Trizell Group is a life sciences group associated with Ferring and the Frederik Paulsen Foundation that has operated across gene therapy and cell therapy development, manufacturing, and commercialization support. Historically, the group has included entities such as Trizell Ltd in the UK, Trizell GmbH in Germany, and Trizell Holding SA in Switzerland, with links to FinVector in Finland. Its programs have included adenoviral interferon alfa-2b gene therapy for malignant pleural mesothelioma, regulatory macrophage-based cell therapy for vascular disease, and prior strategic involvement in advanced cell therapy partnerships. The group has also played a role in the development and manufacturing ecosystem around viral vector products, particularly through FinVector. Overall, Trizell appears to function more as a specialty advanced-therapies operating group than as a single standalone commercial biopharma brand.